Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
SGMO Transcript
Sangamo Therapeutics, Inc. (SGMO) Q4 2025 Earnings Call Transcript
Unknown3-30
The earnings call reflects a mix of positive and negative factors. Positive developments include strong financial metrics, successful funding, and promising results in the Fabry disease program. However, significant risks such as funding challenges, regulatory approval uncertainties, and competitive pressures weigh heavily. The Q&A section highlighted management's evasive responses, particularly regarding Fabry partnerships, which could dampen investor confidence. Without a market cap, it's difficult to predict volatility, but the mixed signals suggest a neutral sentiment for the stock price in the short term.
Sangamo Therapeutics, Inc. (SGMO) Q3 2025 Earnings Call Transcript
Positive11-6
The earnings call highlighted strong financial metrics, including a sufficient cash runway into 2026 and positive clinical data across multiple programs. While the Q&A revealed some uncertainties in partnership negotiations, the FDA's supportive stance on the Fabry disease program and ongoing interest in other platforms provide optimism. The call's overall tone was positive, with strong clinical results and financial health suggesting a likely stock price increase of 2% to 8% over the next two weeks.
Sangamo Therapeutics, Inc. (SGMO) Q2 2025 Earnings Call Transcript
Positive8-8
The earnings call summary indicates strong financial performance with an $18 million upfront fee from Eli Lilly and potential for $1.4 billion in future earnings. The Fabry program shows significant clinical progress, with patients showing improved quality of life and stable cardiac function. The Q&A section reveals positive sentiment from analysts and high potential adoption rates for ST-920. Despite an equity offering, the cash runway is extended, and cost reductions are significant. Overall, the optimistic guidance and strong clinical data suggest a positive stock price movement.
Earnings call transcript: Sangamo Therapeutics faces stock drop after Q1 2025 call
Unknown5-12
The overall sentiment is negative due to the equity offering, which typically dilutes existing shares, and the lack of clear guidance on partnerships and statistical analysis. Although there are positive aspects like reduced expenses and potential partnerships, the uncertainty in partnership success, macroeconomic concerns, and unclear management responses in the Q&A contribute to a negative outlook.
SGMO Slides
SGMO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.